Phytochemicals targeting glycolysis in colorectal cancer therapy: effects and mechanisms of action

Lu Zhan,Fangting Su,Qiang Li,Yueqiang Wen,Feng Wei,Zhelin He,Xiaoyan Chen,Xiang Yin,Jian Wang,Yilin Cai,Yuxia Gong,Yu Chen,Xiao Ma,Jinhao Zeng
DOI: https://doi.org/10.3389/fphar.2023.1257450
IF: 5.6
2023-08-25
Frontiers in Pharmacology
Abstract:Colorectal cancer (CRC) is the third most common malignant tumor in the world, and it is prone to recurrence and metastasis during treatment. Aerobic glycolysis is one of the main characteristics of tumor cell metabolism in CRC. Tumor cells rely on glycolysis to rapidly consume glucose and to obtain more lactate and intermediate macromolecular products so as to maintain growth and proliferation. The regulation of the CRC glycolysis pathway is closely associated with several signal transduction pathways and transcription factors including phosphatidylinositol 3-kinases/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR), adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK), hypoxia-inducible factor-1 (HIF-1), myc, and p53. Targeting the glycolytic pathway has become one of the key research aspects in CRC therapy. Many phytochemicals were shown to exert anti-CRC activity by targeting the glycolytic pathway. Here, we review the effects and mechanisms of phytochemicals on CRC glycolytic pathways, providing a new method of drug development.
pharmacology & pharmacy
What problem does this paper attempt to address?